{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:05:23Z","timestamp":1773835523153,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/ftd.0b013e318278dc69","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T12:00:27Z","timestamp":1354881627000},"page":"112-117","source":"Crossref","is-referenced-by-count":10,"title":["Micromethod for Quantification of Cinacalcet in Human Plasma by Liquid Chromatography\u2013Tandem Mass Spectrometry Using a Stable Isotope-Labeled Internal Standard"],"prefix":"10.1097","volume":"35","author":[{"given":"Giuliana","family":"Cangemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico E.","family":"Verrina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Scurati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Melioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Della Casa Alberighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.semnephrol.2004.06.006","article-title":"Calcimimetic agents for the treatment of secondary hyperparathyroidism.","volume":"24","author":"Goodman","year":"2004","journal-title":"Semin Nephrol"},{"key":"R2-13-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","article-title":"Extracellular calcium sensing and extracellular calcium signaling.","volume":"81","author":"Brown","year":"2001","journal-title":"Physiol Rev"},{"key":"R3-13-20210129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":". Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.","volume":"6","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R4-13-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetics and pharmacodynamic profile of cinacalcet hydrochloride.","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R5-13-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00467-007-0671-3","article-title":"Chronic kidney disease mineral and bone disorder in children.","volume":"23","author":"Wesseling","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R6-13-20210129","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00467-007-0742-5","article-title":". Cinacalcet is efficacious in pediatric dialysis patients.","volume":"23","author":"Silverstein","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R7-13-20210129","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","article-title":". Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.","volume":"23","author":"Muscheites","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R8-13-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00467-009-1294-7","article-title":". Middle-term use of Cinacalcet in paediatric dialysis patients.","volume":"25","author":"Platt","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R10-13-20210129","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":". Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R11-13-20210129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2125.2004.02088.x","article-title":". The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.","volume":"57","author":"Ohashi","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R12-13-20210129","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":". Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.","volume":"47","author":"Nakashima","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R13-13-20210129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00044011-200828100-00004","article-title":". Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single-dose, single-centre study.","volume":"28","author":"Padhi","year":"2008","journal-title":"Clin Drug Invest"},{"key":"R14-13-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpba.2011.05.032","article-title":". I. Quantification of cinacalcet by LC-MSMS using liquid-liquid extraction from 50 L of plasma.","volume":"56","author":"Nirogi","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"R17-13-20210129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0026-0495(98)90064-6","article-title":". SAAMII: simulation, analysis, and modelling software for tracer and pharmacokinetics studies.","volume":"47","author":"Barrett","year":"1998","journal-title":"Metabolism"},{"key":"R18-13-20210129","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1373\/49.7.1041","article-title":"Ion suppression in mass spectrometry.","volume":"49","author":"Annesley","year":"2003","journal-title":"Clin Chem"},{"key":"R19-13-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/ac60298a016","article-title":". Ion specific detection of internal standards labelled with stable isotopes.","volume":"43","author":"Gaffney","year":"1971","journal-title":"Anal Chem"},{"key":"R20-13-20210129","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/rcm.4940","article-title":"Evaluation of the comparability of spectra generated using a tuning point protocol on twelve electrospray ionisation tandem-in-space mass spectrometers.","volume":"25","author":"Champarnaud","year":"2011","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R21-13-20210129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1600-6143.2007.02136.x","article-title":". Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.","volume":"8","author":"Serra","year":"2008","journal-title":"Am J Transplant"},{"key":"R22-13-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM197208032870505","article-title":"Serum drug concentrations as therapeutic guides.","volume":"287","author":"Koch-Weser","year":"1972","journal-title":"N Engl J Med"},{"key":"R24-13-20210129","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":". Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.","volume":"45","author":"Bartelink","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R25-13-20210129","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1211\/jpp.59.8.0001","article-title":". Developing paediatric medicines: identifying the needs and recognizing the challenges.","volume":"59","author":"Ernest","year":"2007","journal-title":"J Pharm Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318278dc69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:40:18Z","timestamp":1620952818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201302000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318278dc69","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}